StockData

Aspen Neuroscience, Inc. (ASPE) shareholders

ASPENasdaqPharmaceutical PreparationsFiscal year ends December 31
$12.00−0.23 (-1.88%)

Close on Nov 17, 2026Market cap –P/E –Yield –

Ownership

Who owns Aspen Neuroscience's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
6 buys · 0 sales
Net bought $68.00M

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
ARCH Venture Partners X, LLC
Joint filing with ARCH Venture Fund X, L.P. (12.90%), ARCH Venture Partners X, L.P. (12.90%) and 9 more
3,754,92212.90%13D (active)Nov 2, 2026
Orbimed Advisors LLC
Joint filing with Orbimed Capital Gp Vii LLC (12.30%)
3,589,13212.30%13D (active)Nov 2, 2026
Abigail P. Johnson
Joint filing with FMR LLC (11.20%)
3,250,00011.20%13G (passive)Oct 30, 2026
Gilead Sciences, Inc.2,879,9969.90%13G (passive)Oct 30, 2026
Qatar Investment Authority1,933,3306.70%13G (passive)Oct 30, 2026
Patrick J. Heron
Joint filing with Frazier Life Sciences X, L.P. (5.80%), Fhmls X, L.P. (5.80%) and 2 more
1,674,3215.80%13G (passive)Nov 2, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares ownedLatest filing
Faheem HasnainExecutive Chair, Director384,679Nov 9, 2026
Damien McDevittSee Remarks, Director561,648Oct 29, 2026
Dalen MeeterChief Financial Officer–Oct 29, 2026
Lisa Johnson-PrattChief Commercial Officer–Oct 29, 2026
Kim RaineriChief Technology Officer–Oct 29, 2026
Jeffrey Lee BoernekeGeneral Counsel and Secretary–Oct 29, 2026
Capital GP VII LLC OrbiMedDirector, 10% owner–Nov 4, 2026
Peter A. ThompsonDirector, 10% owner3,589,132Nov 4, 2026
Advisors Llc OrbimedDirector, 10% owner3,589,132Nov 4, 2026
Andrew SpaventaDirector308,076Nov 2, 2026
Thomas O. DanielDirector–Oct 29, 2026
Caryn PetersonDirector–Oct 29, 2026
Cynthia Dorothy PerettieDirector–Oct 29, 2026
Douglas Carl FisherDirector–Oct 29, 2026
ARCH Venture Fund XIV, L.P.10% owner–Nov 2, 2026
Paul L. Berns10% owner–Nov 2, 2026
ARCH Venture Fund X Overage, L.P.10% owner–Nov 2, 2026
ARCH Venture Partners X Overage, L.P.10% owner–Nov 2, 2026
ARCH Venture Partners X, LLC10% owner–Nov 2, 2026
Steven Gillis10% owner–Nov 2, 2026
Keith Crandell10% owner–Nov 2, 2026
Robert Nelsen10% owner–Nov 2, 2026
Kristina Burow10% owner–Nov 2, 2026
ARCH Venture Partners X, L.P.10% owner–Nov 2, 2026
ARCH Venture Fund X, L.P.10% owner2,361,074Nov 2, 2026
ARCH Venture Partners XIV, L.P.10% owner1,200,000Nov 2, 2026
ARCH Venture Partners XIV, LLC10% owner–Nov 2, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Faheem Hasnain
Executive Chair, Director
Nov 5, 2026Award+321,672––348,330
Peter A. Thompson
Director, 10% owner
Nov 2, 2026Buy+1,000,000$15.00$15.00M3,589,132
Peter A. Thompson
Director, 10% owner
Nov 2, 2026Conversion+507,119––2,589,132
Peter A. Thompson
Director, 10% owner
Nov 2, 2026Conversion+625,743––2,082,013
Peter A. Thompson
Director, 10% owner
Nov 2, 2026Conversion+616,984––1,456,270
Peter A. Thompson
Director, 10% owner
Nov 2, 2026Conversion+642,745––839,286
Peter A. Thompson
Director, 10% owner
Nov 2, 2026Conversion+196,541––196,541
Advisors Llc Orbimed
Director, 10% owner
Nov 2, 2026Buy+1,000,000$15.00$15.00M3,589,132
Advisors Llc Orbimed
Director, 10% owner
Nov 2, 2026Conversion+507,119––2,589,132
Advisors Llc Orbimed
Director, 10% owner
Nov 2, 2026Conversion+625,743––2,082,013
Advisors Llc Orbimed
Director, 10% owner
Nov 2, 2026Conversion+616,984––1,456,270
Advisors Llc Orbimed
Director, 10% owner
Nov 2, 2026Conversion+642,745––839,286
Advisors Llc Orbimed
Director, 10% owner
Nov 2, 2026Conversion+196,541––196,541
ARCH Venture Fund X, L.P.
10% owner
Nov 2, 2026Buy+1,200,000$15.00$18.00M1,200,000
ARCH Venture Fund X, L.P.
10% owner
Nov 2, 2026Conversion+214,355––1,161,074
ARCH Venture Fund X, L.P.
10% owner
Nov 2, 2026Conversion+295,490––946,719
ARCH Venture Fund X, L.P.
10% owner
Nov 2, 2026Conversion+286,304––651,229
ARCH Venture Fund X, L.P.
10% owner
Nov 2, 2026Conversion+298,258––364,925
ARCH Venture Fund X, L.P.
10% owner
Nov 2, 2026Buy+66,667$15.00$1.00M66,667
ARCH Venture Fund X, L.P.
10% owner
Nov 2, 2026Conversion+259,948––1,393,848
ARCH Venture Fund X, L.P.
10% owner
Nov 2, 2026Conversion+295,490––1,133,900
ARCH Venture Fund X, L.P.
10% owner
Nov 2, 2026Conversion+286,304––838,410
ARCH Venture Fund X, L.P.
10% owner
Nov 2, 2026Conversion+298,258––552,106
ARCH Venture Fund X, L.P.
10% owner
Nov 2, 2026Conversion+187,182––253,848
ARCH Venture Fund X, L.P.
10% owner
Nov 2, 2026Buy+66,666$15.00$999.99K66,666
ARCH Venture Partners XIV, L.P.
10% owner
Nov 2, 2026Buy+1,200,000$15.00$18.00M1,200,000
Andrew Spaventa
Director
Nov 2, 2026Conversion+180,221––180,221
Andrew Spaventa
Director
Nov 2, 2026Conversion+70,194––70,194
Faheem Hasnain
Executive Chair, Director
Nov 2, 2026Conversion+7,120––7,120
Faheem Hasnain
Executive Chair, Director
Nov 2, 2026Conversion+14,316––14,316
Faheem Hasnain
Executive Chair, Director
Nov 2, 2026Conversion+14,913––14,913

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

See a number that looks wrong?